Abaloparatide

What is Abaloparatide?

Abaloparatide is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP). It is primarily used for the treatment of postmenopausal women with osteoporosis who are at high risk for fractures. Abaloparatide helps increase bone density and strength by stimulating new bone formation, reducing the risk of fractures, particularly in the spine and non-vertebral sites.

How to Use Abaloparatide?

• Dosage: The recommended dose of abaloparatide is 80 micrograms administered subcutaneously (under the skin) once daily.
• Administration: It is injected into the lower stomach area (abdomen), avoiding a 2-inch area around the navel. Rotate injection sites to avoid skin irritation.
• Instructions: The medication comes in a pre-filled pen, and patients are instructed on proper self-injection techniques by their healthcare provider.
• Treatment Duration: The use of abaloparatide is typically limited to 2 years during a patient's lifetime due to the risk of potential side effects from long-term use.

What are the Side Effects?

Common side effects include:

• Dizziness.
• Nausea.
• Fatigue.
• Headache.
• Upper abdominal pain.
• Injection site reactions (redness, swelling, or pain).

Less common but more serious side effects include:

• Orthostatic hypotension: Some people may experience a sudden drop in blood pressure when standing up, which can lead to dizziness or fainting.
• Hypercalcemia (high levels of calcium in the blood): Symptoms can include muscle weakness, confusion, or abnormal heart rhythms.
• Increased risk of osteosarcoma: Animal studies have shown an increased risk of a type of bone cancer with long-term use of abaloparatide. However, the significance of this risk in humans is not fully known.

What are the Precautions?

• Bone cancer risk: Due to the potential risk of osteosarcoma, abaloparatide should be used with caution in patients with a history of bone cancer or other conditions that may increase the risk of osteosarcoma.
• Kidney function: Patients with severe kidney disease should use abaloparatide with caution, as it may exacerbate hypercalcemia.
• Orthostatic hypotension: Patients should be advised to get up slowly from sitting or lying positions to avoid dizziness or fainting.

How to Store Abaloparatide?

• Refrigerate at 2°C to 8°C (36°F to 46°F) before first use. After the first injection, the pen can be stored at room temperature (up to 30°C or 86°F) for up to 30 days.
• Do not freeze abaloparatide.
• Keep the pen cap on when not in use, and store it away from direct sunlight and heat.
• Keep out of reach of children.

Abaloparatide  is an effective treatment for increasing bone mineral density and reducing fracture risk in postmenopausal women with osteoporosis. Proper self-administration and awareness of potential side effects, especially the rare but serious risk of bone cancer, are essential during the treatment.